Unicycive Therapeutics (UNCY)
(Delayed Data from NSDQ)
$0.34 USD
-0.01 (-1.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.35 +0.01 (3.61%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Unicycive Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 1 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 1 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 21 | 19 | 9 | 2 | 2 |
Income After Depreciation & Amortization | -21 | -18 | -9 | -2 | -2 |
Non-Operating Income | -10 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 1 | 0 | 0 |
Pretax Income | -31 | -18 | -10 | -2 | -2 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -31 | -18 | -10 | -2 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -31 | -18 | -10 | -2 | -2 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -20 | -18 | -8 | -2 | -2 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -21 | -18 | -9 | -2 | -2 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 24.54 | 15.06 | 11.68 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.60 | -1.20 | -0.86 | NA | NA |
Diluted Net EPS (GAAP) | -1.28 | -1.20 | -0.86 | -0.27 | NA |
Fiscal Year end for Unicycive Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 7.40 | 9.20 | 6.31 | 5.94 | 4.33 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.40 | -9.20 | -6.31 | -5.94 | -4.33 |
Non-Operating Income | 17.27 | -11.74 | -1.47 | 1.62 | 0.52 |
Interest Expense | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 |
Pretax Income | 9.85 | -20.96 | -7.80 | -4.33 | -3.84 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 9.85 | -20.96 | -7.80 | -4.33 | -3.84 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 9.86 | -20.96 | -7.80 | -4.33 | -3.84 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 94.05 | 34.91 | 24.54 | 32.63 | 15.24 |
Diluted EPS Before Non-Recurring Items | -0.15 | -0.27 | -0.16 | -0.13 | -0.29 |
Diluted Net EPS (GAAP) | -0.15 | -0.61 | 0.11 | -0.13 | -0.29 |